Dr. Gupta on the Investigation of Enfortumab Vedotin With or Without Additional Therapy in mUC

Video

In Partnership With:

Shilpa Gupta, MD, discusses the investigation of enfortumab vedotin with or without additional therapy in cisplatin-ineligible metastatic urothelial carcinoma.

Shilpa Gupta, MD, director, Genitourinary Medical Oncology, Taussig Cancer Institute, co-leader, Genitourinary Oncology Program, Cleveland Clinic, discusses the investigation of enfortumab vedotin-ejfv (Padcev) with or without additional therapy in cisplatin-ineligible metastatic urothelial carcinoma (mUC).

The phase 1/2 EV-103 trial (NCT03288545) is investigating enfortumab vedotin alone and with different combinations of anticancer therapies. In the cisplatin-ineligible patient cohort, the combination of enfortumab vedotin and pembrolizumab (Keytruda) showed remarkable activity and promising overall survival, Gupta explains. Additionally, cohort K randomized patients to enfortumab vedotin vs enfortumab vedotin and pembrolizumab in cisplatin-ineligible patients, Gupta adds.

The combination of enfortumab vedotin and pembrolizumab resulted in beneficial response rates compared with enfortumab vedotin alone; the survival data are not mature and toxicity was higher with the combination therapy, Gupta concludes.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD